Sovilnesib is under clinical development by Volastra Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sovilnesib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sovilnesib overview

Sovilnesib (AMG-650) is under development for the treatment of triple-negative breast cancer (TNBC), platinum-resistant high grade serous ovarian cancer, primary peritoneal cancer, fallopian tube cancer, serous endometrial cancer and other solid tumors with TP53 gene mutation (TP53MUT). The drug candidate is administered orally as tablet. It acts by targeting KIF18A.

Volastra Therapeutics overview

Volastra Therapeutics discovers and develops drugs for oncology indications. The company is investigating K1F18A, a mitotic kinesin; and CRISPR hits programs to find synthetic lethal targets. Volastra Therapeutics utilizes its proprietary CINtech (chromosomal instability technology) platform to identify and create drugs for cancer. The company works in partnership with Weill Cornell Medicine, Dewpoint Therapeutics Inc, and other companies to advance its science and create cancer therapies. It operates across the US. Volastra Therapeutics is headquartered in New York city, New York, the US.

For a complete picture of Sovilnesib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.